C5 and COVID-19: Moreover, the well-established complement inhibitor eculizumab that prevents cleavage of C5, and a neutralizing antibody to C5a, have shown beneficial effect in patient subgroups with COVID-19 (14, 16) in line with one paper showing increased levels of C5a in COVID-19 patients at admission (17).